Recurrent use of newer oral contraceptives and the risk of venous thromboembolism

Human Reproduction

Volumn 15, Issue 4, 2000, Pages 817-821

  Suissa, S ^a,e   Spitzer, W O ^a   Rainville, B ^b   Cusson, J ^c   Lewis, M ^c   Heinemann, L ^d  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d ZEG   (Germany)

^e Division of Clinical Epidemiology   (Canada)

Author keywords

Deep venous thrombosis; Epidemiological study; Pulmonary embolism; Second and third generation oral contraceptives

Indexed keywords

LOW DOSE ORAL CONTRACEPTIVE; ORAL CONTRACEPTIVE AGENT;

ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FEMALE; GERMANY; HUMAN; LUNG EMBOLISM; ORAL CONTRACEPTION; RISK ASSESSMENT; THROMBOEMBOLISM; UNITED KINGDOM;

EID: 0034108798     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/15.4.817     Document Type: Article

References (20)

1. Benagiano, G. (1998) Venous thromboembolism and the pill: learning from the past -an endless saga. Hum. Reprod., 13, 1115-1116.
2. Bloemenkamp, K.W.M., Rosendaal, F.R., Hemerhosrt, RM. et al. (1995) Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet, 346, 1593-1596.
3. Parley, T.M.M., Meirik, O., Marmot, M.G. et al. (1998) Oral contraceptives and risk of venous thromboembolism: impact of duration of use [Letter]. Contraception, 57, 61-65.
4. Farmer, R.D.T., Lawrenson, R.A., Thompson, C.R. et al. (1997) Populationbased study of risk of venous thromboembolism associated with various oral contraceptives. Lancet, 349, 83-88.
5. Farmer, R.D.T., Todd, J.C., Lewis, M.A. et al. (1998) The risks of venous thromboembolism disease among German women using oral contraceptives: a database study. Contraception, 57, 67-70.
6. Guess, H.A. (1989) Behaviour of the exposure odds ratio in a case-control study when the hazard function is not constant over time. J. Clin. Epidemiol., 42, 1179-1184.
7. Heinemann, L.A.J., Lewis, M.A., Abmann, A. et al. (1996) Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third-generation oral contraceptives? Phannacepidemiol. Drug Safety, S, 285-294
8. Jick, H., Jick, S.S., Gurewich, V. et al. (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components [See comments]. Lancet, 346, 1589-1593.
9. Lidegaard, O., Edstrom, B. and Kreiner, S. (1998) Oral contraceptives and venous thromboembolism: A case control study. Contraception, 57, 291-301.
10. Miettinen, O.S. and Caro, J.J. (1989) Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. J. Clin. Epidemiol., 42, 325-331.
11. Mills, A. (1997) Combined oral contraception and the risk of venous thromboembolism. Hum. Reprod., 12, 2595-2598.
12. Petri, H. and Urquhart, J. (1991) Channelling bias in the interpretation of drug effects. Statist. Med., 10, 577-581.
13. Poulter, N.R., Parley, T.M.M., Chang, C.L. et al. (1996) Safety of combined oral contraceptive pills [Letter]. Lancet, 347, 547.
14. Rosenberg, L., Bégaud, B., Bergman, U. et al. (1996) What are the risks of third-generation oral contraceptives? Are third-generation oral contraceptives safe? Hum. Reprod., 11, 687-693.
15. SAS/STAT Software (1996) Changes and Enhancements. Release 6.11 edn. SAS Institute, Inc., Cary, NC.
16. Spitzer, W.O., Lewis, M.A., Heinemann, L.A. et al. (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women [see comments]. Br. Med. J., 312, 83-88.
17. Suissa, S. and Spitzer, W.O. (1998) Methodological limitations in comparing the risks of newer oral contraceptives [Letter]. Contraception, 57, 61-65.
18. Suissa, S., Biais, L., Spitzer, W.O. et al. (1997) First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception, 56, 141-146.
19. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995a) Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception [see comments]. Lancet, 346, 1575-1582.
20. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995b) Effect of different progrestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet, 346,1582-1588.